You are here

Adaptimmune

Second-quarter catalysts for the smaller players

Second-quarter catalysts for the smaller players

EP Vantage

Fulcrum Therapeutics

Gemini Therapeutics

Flag link:

Asco 2020 movers – cell therapy companies dominate the risers

Asco 2020 movers – cell therapy companies dominate the risers

EP Vantage

Flag link:

Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential

Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential

MedCity News

Flag link:

Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies

Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies

BioSpace

drug development

Flag link:

Struggling Adaptimmune gets a boost from the FDA as T-cell cancer drug wins an inside track at the agency

Struggling Adaptimmune gets a boost from the FDA as T-cell cancer drug wins an inside track at the agency

Endpoints

regenerative medicine

Flag link:

Q&A: Adaptimmune’s Elliot Norry on cell therapy

Q&A: Adaptimmune’s Elliot Norry on cell therapy

Pharmaforum

Flag link:

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune reports zero responses across three T cell therapy trials

BioCentury

t-cell therapies

clinical trials

Flag link:

Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study

Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study

CP Wire

Flag link:

Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study

Flag link:

Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment

Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment

CP Wire

Flag link:

Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment

Flag link:

Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug

Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug

Endpoints

TCR therapeutics

Flag link:

After setback, Adaptimmune revamps T cell study

After setback, Adaptimmune revamps T cell study

BioPharma Dive

Flag link:

Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now

Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now

Endpoints

myxoid round cell liposarcoma

cancer immunotherapy

Flag link:

These 5 Biotech Stocks Under $10 Are About to Break Out

These 5 Biotech Stocks Under $10 Are About to Break Out

TheStreet.com

Sangamo BioSciences

Flag link:

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration

Yahoo

Flag link:

9 Biotech Picks for 2016

9 Biotech Picks for 2016

Barron's

Intra-Cellular Therapies

Seres Therapeutics

Neurocrine Biosciences

Flag link:

Adaptimmune pockets GSK payouts after tripling size of TCR trial

Adaptimmune pockets GSK payouts after tripling size of TCR trial

Fierce Biotech

synovial sarcoma

Flag link:

3 Biotech Stocks Wall Street Hates

3 Biotech Stocks Wall Street Hates

Motley Fool

Northwest Biotherapeutics

Flag link:

Pages